On the stock market since 2014, it operates in the world of health and science. It has 19 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Debt is low and cash is strong; the finances stand solid.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Growth: Sales growth trails the sector average.
Business Quality: Profit power and business quality trail similar companies in the sector.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
An investor who bought at the very peak is down 84% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $97.7M in the vault; even if every debt were paid off, $96.9M would remain.
Over the last 12 months, company executives reported 33 buys and 3 sells. Management buying with its own money is usually read as a good sign.
The average analyst price target is $25.00 — 119% above today’s price.
A loss of $37.9M against $0 in annual sales.
The growth engine is running at low revs right now. Report-card grade: 16/100.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 19/100.
On our five-subject report card, BNTC sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: BNTC is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (29/100) says the stock isn’t cheap.